Circulating short chain fatty acid levels and body composition in type 2 diabetes mellitus

2型糖尿病患者循环短链脂肪酸水平和身体成分

阅读:1

Abstract

Background: Short-chain fatty acids (SCFAs) may play key functional roles in the pathophysiology of type 2 diabetes (T2D) through regulating energy intake and substrate metabolism. Body composition, including fat tissue, muscle tissue and the pattern of their distribution in the body, can represent health status and be the cause or consequence of T2D complications. The aim of this study was to explore the relationship between serum SCFA levels and body composition distribution in patients with T2D. Methods: This observational cross-sectional study enrolled 430 patients with T2D from October 2016 to June 2020. The levels of nine kinds of SCFAs in serum were measured using liquid chromatography mass spectrometry. Body composition, including lean tissue and fat tissue, was measured once using bioimpedance spectroscopy at enrollment. Results: The mean age of the patients was 61.7 ± 12.3 years and 54.0% were male. Multivariate linear analysis revealed that the patients with the highest tertile of serum methylbutyrate level (β = -0.81, 95% CI = -1.56, -0.06, p = 0.03) and valerate/isovalerate ratio (β = -1.15, 95% CI = -1.86, -0.44, p = 0.002) had a lower fat tissue index (FTI). In subgroup analysis, the negative association of FTI with serum methylbutyrate level and valerate/isovalerate ratio was only found in the patients who were older, female, and had glycated hemoglobin ≤ 7%, urinary albumin-creatinine ratio < 30 mg/g, homeostatic model assessment for insulin resistance ≤ median value, and body mass index < 30 kg/m(2). Conversely, none of the nine SCFAs were associated with lean tissue index. Conclusions: This study found that T2D patients with a higher circulating methylbutyrate level and serum valerate/isovalerate ratio had lower FTI. The relationship was consistent in older, female patients with well-controlled glucose. Further research is needed to analyze the interactions between SCFAs and body composition with clinical metabolic outcomes in T2D patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。